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Abstract
Background: Hepatocellular carcinoma (HCC) is frequently preceded by hepatitis virus infection or alcohol abuse.
Genetic backgrounds may increase susceptibility to HCC from these exposures.
Methods: Mitochondrial DNA (mtDNA) of peripheral blood, tumor, and/or adjacent non-tumor tissue from 49
hepatitis B virus-related and 11 alcohol-related HCC patients, and from 38 controls without HCC were examined for
single nucleotide polymorphisms (SNPs) and mutations in the D-Loop region.
Results: Single nucleotide polymorphisms (SNPs) in the D-loop region of mt DNA were examined in HCC patients.
Individual SNPs, namely the 16266C/T, 16293A/G, 16299A/G, 16303G/A, 242C/T, 368A/G, and 462C/T minor alleles,
were associated with increased risk for alcohol- HCC, and the 523A/del was associated with increased risks of both
HCC types. The mitochondrial haplotypes under the M haplogroup with a defining 489C polymorphism were
detected in 27 (55.1%) of HBV-HCCand 8 (72.7%) of alcohol- HCC patients, and in 15 (39.5%) of controls.
Frequencies of the 489T/152T, 489T/523A, and 489T/525C haplotypes were significantly reduced in HBV-HCC
patients compared with controls. In contrast, the haplotypes of 489C with 152T, 249A, 309C, 523Del, or 525Del
associated significantly with increase of alcohol-HCC risk. Mutations in the D-Loop region were detected in 5
adjacent non-tumor tissues and increased in cancer stage (21 of 49 HBV-HCC and 4 of 11 alcohol- HCC, p < 0.002).
Conclusions: In sum, mitochondrial haplotypes may differentially predispose patients to HBV-HCC and alcohol-
HCC. Mutations of the mitochondrial D-Loop sequence may relate to HCC development.
Background
Hepatocellular carcinoma (HCC) is the fifth most fre-
quent cancer and the third leading cause of cancer
death worldwide, with over a half million mortality
every year [1]. HCC is also common in China. The
recent report for annual incidence and mortality in
China were 300,000 and 306,000 cases [2,3]. This dis-
ease is strongly associated with several risk factors,
including chronic hepatitis B virus (HBV) and chronic
hepatitis C virus (HCV) infection, and alcohol abuse [4].
HBV infection is a challenging health issue in China,
where about 93 million peoples are HBV carriers and
30 million have chronic B hepatitis [5]. Alcohol abuse is
also on the rise in China and about 6.6% of males and
0.1% of females are diagnosed with alcohol dependence
[6]. Many of these patients develop liver diseases, such
as alcoholic hepatitis and cirrhosis, which are prone to
HCC.
Hepatitis virus infection and alcohol abuse are asso-
ciated with increased oxidative stress in liver cells,
resulting in DNA changes including mitochondrial DNA
(mtDNA) instability [7,8]. The human mitochondrial
genome is 16 kb in length and a closed-circular duplex
molecule that contains 37 genes, including two riboso-
mal RNAs and complete set of 22 tRNAs [9]. mtDNA is
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acquires mutations at a higher rate than nuclear DNA
because of high levels of reactive oxygen species (ROS),
lack of protective histones, and limited capacity for
DNA repair in mitochondria [10-12]. Thus, somatic
mtDNA mutations occur in a wide variety of degenera-
tive diseases and cancers [13,14], and can be homoplas-
mic by clonal expansion [15,16] or heteroplasmic in
tumor tissues [17,18]. In many cancers, including hepa-
titis virus-related HCC, somatic mutations are frequently
located in mtDNA noncoding region called D-Loop
[19,20]. This region is important for regulating both
replication and expression of the mitochondrial genome
because it contains the leading-strand origin of replica-
tion and the main promoter for transcription [21]. Etha-
nol also increases ROS generation in hepatic
mitochondria and is capable of inducing multiple hepa-
tic mitochondrial DNA deletions [8,22]. Somatic muta-
tions in mitochondria have been rarely studied in
alcohol-related HCC patients.
Sequence changes have been examined extensively in
the D-Loop in cancers [17,19,20], but it is not clear
whether those changes represent real somatic muta-
tions or single nucleotide polymorphisms (SNPs),
because blood mitochondria DNAs were not analyzed.
Although some studies focus on sequence variant
determination using blood DNA, only few SNPs have
been selected for predicting cancer risk and their pre-
dictive values are still unclear [23-26]. The D-loop
contains a length of 1122 bps (nucleotide 16024-16569
and 1-576) refers to mitochondria database http://
www.mitomap.org In this study, we sequenced a region
of about 1 kb franking almost all the D-Loop in can-
cerous and adjacent noncancerous tissues, and blood
from the same patients of both hepatitis B virus-
related (HBV-HCC) and alcohol-related HCC (alcohol-
HCC). Many polymorphisms and somatic mutations
were identified. When compared with controls without
HCC, these genetic information are particular valuable
to predict risk and to reveal natural history of the two
types of HCC.
Methods
Tissue specimens and mtDNA extraction
We obtained histologically confirmed cancerous and cor-
responding noncancerous liver tissues from patients of 11
alcohol-HCC (average alcohol consumption higher than
40 g per day for at least five years) and 49 HBV- HCC,
and liver tissues with no detectable malignancies except
hepatic hemangioma from 38 control patients at the
Fourth Hospital of Hebei Medical University. The heman-
gioma patients under surgery were selected as control just
because it was vascular malformation with developmental
aberration and we can obtain normal liver tissue from the
specimen. Clinical characteristics of HCC patients and
controls were listed in Table 1 and only one patient with
alcohol abuse was found in the virus group. The liver
function of all patients belonged to the Child-Pugh A or B
cirrhosis index with total bilirubin levels less than 30
umol/L. No difference in tumor pathology could be found
between alcohol-HCC and HBV-HCC. The HBV-HCC
patients were apparently carriers for HBV. The histological
specimens were independently reviewed by two patholo-
gists. If initial examination did not agree, consensus was
obtained after joint microscopic evaluation. All tissues
were kept in liquid nitrogen immediately after surgical
resection according to guideline of the human tissue
research committee at the hospital, Written informed con-
sent was obtained from all participants prior to enroll-
ment. Mitochondria were isolated from liver tissue and
mtDNA was extracted with the Mitochondrial DNA
Extraction Kit (Genmed Scientific Inc, Shanghai, China).
Whole blood was obtained from corresponding HCC
patients and controls except in one case without an avail-
able blood sample in the alcohol-HCC group. Mitochon-
dria isolation and mtDNA extraction were carried out
using the Blood Mitochondrial DNA Extraction Kit
(Genmed Scientific Inc.). All mtDNA was stored at -20°C.
PCR amplification and sequence analysis
The forward primer 5′-CCCCATGCTTACAAG-
CAAGT-3′ (nucleotide 16190-16209) and reverse pri-
mer 5′-GCTTTGAGGAGGTAAGCTAC-3′ (nucleotide
Table 1 Clinical data in HBV-HCC, alcohol-HCC patients and controls
HBV-HCC (n = 49) Alcohol-HCC (n = 11) Control (n = 38)
Age (years) 52.20 ± 9.86 58.36 ± 8.11 53.08 ± 10.98
Sex (M/F) 43/6 10/1 18/20
Child-Pugh Grade (B/A) 2/47 0/11 -
Alcohol abuse 1 11 0
Positive HBV surface antigen 49 0 0
Positive HBV anti-surface antibody 0 0 0
Tumor stage (I/II/III) 13/36/0 2/5/3
a -
aOne alcohol-HCC patient did not have sufficient tissues for stage classification.
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product from mtDNA D-Loop region as described
previously [27]. PCR was performed according to the
protocol of PCR Master Mix Kit (Promega, Madison,
WI) and purified prior to sequencing. Cycle sequencing
was carried out with the Dye Terminator Cycle Sequen-
cing Ready Reaction Kit (Applied Biosystem, Foster City,
CA) and the products were then separated on the
ABIPRISM Genetic Analyzer 3100 (Applied Biosystem).
Mutations and polymorphisms were confirmed by
repeated analyses from both strands. SNPs were identi-
fied directly from blood mitochondria.
Statistical analysis
Paired and unpaired Student’s t-test were used as appro-
priate to determine the differences SNP distribution
within the D-Loop region and the number of SNPs per
patient among groups. Fisher’s exact test and chi-square
were used accordingly to analyze dichotomous values,
such as presence or absence of an individual SNP in
each patient group. A p value of less than 0.05 was con-
sidered statistically significant. The Wilcoxon rank sum
test was used to determine statistical differences among
age, sex and Child-Pugh grade. Pairwise linkage disequi-
librium between SNPs was done using GENEPOP
http://wbiomed.curtin.edu.au/genepop
Results
SNPs in reference to GenBank accession AC_000021
were detected in 92 sites of the 982-bp mitochondria D-
Loop region from blood samples. The minor allele fre-
quency ranged from 1.0% (1/98) to 46.90 (46/98). Of
these, 13 SNPs (16A/T, 44C/CC, 56A/G, 245T/C, 275G/
A, 310T/G, 368A/G, 449T/C, 454T/C, 570C/G, 16259C/
G, 16267C/G, and 16445T/C) were new, as they were
not reported in a mitochondria database http://www.
mitomap.org. SNP numbers ranged from 3 to 13 for
individuals, no statistical difference for SNP numbers in
each individual referring to sex was observed. The pair-
wise linkage disequilibrium analysis between the SNPs
identified in the D-loop of HCC patients and controls
was performed, the paired loci with linkage disequili-
brium p value less than 0.001 were listed(Additional File
1, Table S1).
HBV-HCC patients clearly showed a significantly
higher SNP frequency referring to the numbers of SNPs
identified in each individual than control patients (Table
2). A tendency toward an increased SNP frequency was
also observed for alcohol-HCC patients but did not
reach statistical significance. Next, distributions or spec-
tra of relative frequencies across 92 SNP sites from
blood of patients in the HBV-HCC, alcohol-HCC, and
control groups were compared to provide the topology
of polymorphisms (Fig. 1). The diversity of distribution
was analyzed by paired t-test and SNPs in HBV-HCC
patients apparently showed distinct spectrum from con-
trol (p = 0.0001). The SNP distribution in the D-Loop
region in alcohol-HCC appeared to be less differentiable
from HBV-HCC and control.
When individual SNPs were analyzed between HCC
and control, a statistically significant increase of SNP
frequency was observed for 16298C and 523del alleles in
HBV-HCC (p < 0.05) and for 16293G, 523del, and
525del alleles in alcohol-HCC (p < 0.05) patients (Table
3). The trend was next determined with all 3 groups
using t test. Additional SNPs (16266T, 16299G, 16303A,
242T, 368G, and 462T) were significantly associated
with the tendency toward the increased risk for alcohol-
HCC. In contrast, the 152C allele was correlated with
reduced risk, especially for alcohol-HCC. The remaining
81 SNPs were not associated with either type of HCC.
T h eMh a p l o g r o u p ,d e f i n e db yt h ep r e s e n c eo f4 8 9 C ,
was used to stratify the subject
groups for subsequent analysis. When the status of the
489C was combined with the above frequent SNPs, pre-
dictive values for the risks of HBV-HCC and alcohol-
HCC were immediately detected in several haplotypes
(Table 4). Frequencies of the 489T/152T, 489T/523A,
and 489T/525C haplotypes were significantly reduced in
HBV-HCC patients compared with controls. In contrast,
the haplotypes of 489C with 152T, 249A, 309C, 523Del,
or 525Del associated significantly with increase of alco-
hol-HCC risk. The haplotypes 489C/152T, 489C/523Del,
and 489C/525Del further predicted the risk of alcohol-
HCC in comparison with HBV-HCC. The other SNP-
defined haplotypes did not associate with either type of
HCC.
In addition to SNPs, mutations in the D-Loop region
were identified by comparing the sequences in tumor
and adjacent non-tumor areas with the genotype in
blood of the same subject, except for patient #1 whose
blood DNA was not available for sequence analysis
(Table 5). Instead, sequences from tumor and non-
tumor tissues were compared for this patient. Mutations
were detected in 21 of 49 HBV-HCC and in 4 of 11
alcohol-HCC patients. For 38 controls, identical D-Loop
sequences were seen between blood and liver mtDNA of
t h es a m ep a t i e n t ,c o n f i r m i n g no mutations in liver tis-
sues separated from hemangiomas. When statistical
Table 2 Average SNP frequency in the mitochonrial DNA
D-Loop for each group
Control
(n = 38)
HBV-HCC
(n = 49)
Alcohol-HCC
(n = 10)
SNPs/patient 6.7 ± 2.0
b 8.5 ± 2.2 8.0 ± 1.9
P value
a 0.0002 0.0730
aT test.
bMean ± standard deviation
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significant increase of mutation frequency was observed
in both HBV-HCC (Fisher’s exact test, p = 0.0001) and
alcohol-HCC (Fisher’s exact test, p = 0.0016). Four
patients, #18, #27, #60, and #65, in HBV-HCC and one
patient, #14, in alcohol-HCC had mutations in non-
tumor areas. These early mutations were localized at the
same 309 site with either deletion or insertion of C.
Discussion
An increase of mutations in the D-Loop region of mito-
chondria has been reported in HCC [19,20,27]. To pre-
dict cancer risk, selected SNPs in the D-Loop region
have been examined in other tumor types [23-26]. The
current study has extended those analyses to determine
SNPs and mutations in a continuous sequence of mito-
chondrial DNA between nucleotides 16190 and 583 in
patients of HCCs with different etiology, namely, HBV
or alcohol abuse. This provides an opportunity to dis-
cover new SNPs and demonstrates that analysis of blood
DNA along with tumor materials from the same patient
is surely critical to differentiate SNPs from mutations.
SNPs appear to be common in this Chinese popula-
tion with average of 7 to 9 for each patient in reference
to GenBank AC_000021 sequence for Caucasians. The
actual number of SNPs may be less if the reference
sequence was of Chinese origin. These SNPs are less
likely to arise from mutations in blood mitochondria
DNA because the same SNPs were observed in corre-
sponding non-tumor tissues. Also, they are homoplasmy
with single peak detected at each SNP site. This suggests
that the SNPs are germline sequence variants and also
raises the possibility that some of homoplasmic muta-
tions may actually have been SNPs in previous studies
that do not have blood DNA for comparison. When
compared with control, frequent SNPs in both HBV-
HCC and alcohol-HCC patients provide the first evi-
dence that a high SNP frequency seem to predisposes
patients to HCC regardless of different etiology (Table
2). It is still unclear how SNPs in the D-loop transcrip-
tion-regulatory region increase the risk of cancers,
although these genetic changes have been frequently
Figure 1 Distribution (spectrum) of D-Loop SNPs at 92 sites (x-axis) and their relative frequencies in percentage within each group
(y-axis). Paired T-test: p = 0.0001 (HBV-HCC vs. control); p = 0.3416 (Alcohol-HCC vs. control); p = 0.2817 (HBV-HCC vs. Alcohol-HCC).
Table 3 SNP sites showing frequency difference between
HCC and control
Nucleotide
a Control HBV-HCC Alcohol-HCC Trend-p value
b
16266 C/T 37/1 (2.6)
c 49/0 (0.0) 8/2 (20.0) 0.0038
d
P value 0.4368 0.1058
16293 A/G 38/0 (0.0) 48/1 (2.0) 8/2 (20.0) 0.0042
P value >0.9999 0.0399
16298 T/C 35/3 (7.9) 37/12 (24.5) 9/1 (10.0) 0.0992
P value 0.0495 >0.9999
16299A/G 38/0 (0.0) 49/0 (0.0) 9/1 (10.0) 0.0123
P value >0.9999 0.2083
16303 G/A 38/0 (0.0) 49/0 (0.0) 9/1 (10.0) 0.0123
P value >0.9999 0.2083
152 T/C 30/8 (21.1) 31/18 (36.7) 10/0 (0.0) 0.0340
P value 0.1130 0.1767
242 C/T 38/0 (0.0) 49/0 (0.0) 9/1 (10.0) 0.0123
P value >0.9999 0.2083
368 A/G 38/0 (0.0) 49/0 (0.0) 9/1 (10.0) 0.0123
P value >0.9999 0.2083
462 C/T 38/0 (0.0) 49/0 (0.0) 9/1 (10.0) 0.0123
P value >0.9999 0.2083
523 A/del 32/6 (15.8) 31/18 (36.7) 4/6 (60.0) 0.0122
P value 0.0302 0.0092
525C/del 30/8 (21.1) 31/18 (36.7) 4/6 (60.0) 0.0483
P value 0.1130 0.0447
aFisher’s exact test: HCC vs. control.
bChi-square test for trend.
cNumber in parenthesis: SNP percentage.
dNumber in bold: p < 0.05.
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production of ROS is enhanced when the mitochondrial
transcription is altered [28]. This ROS-mediated
mechanism may promote tumor formation. The spec-
trum across 92 SNP sites further shows a diverse pat-
tern of SNPs in HBV-HCC patients compared with
control (Fig. 1). The diversity was not prominent for
alcohol-HCC, most likely due to small sample size.
A new study is required to recruit more patients to
examine the role of mtDNA D-Loop SNP frequency in
alcohol-HCC risk.
From the SNP spectrum (Fig. 1), it is very easy to spot
potential SNP sites showing either increase or decrease
of frequency. In most SNP sites, the patterns of SNP
distribution among HBV-HCC, alcohol-HCC, and con-
trol are very much overlapping each other. The weight
for the sequence diversity appears to fall on the
16298T/C and 523A/del two SNPs for HBV-HCC, and
16293G/A, 523A/del, and 525C/del 3 SNPs for alcohol-
HCC (Table 3). Several rare alleles defined as being less
than 5% of allele frequency, though required confirma-
tion in a larger population, tend to predict the risk of
alcohol-HCC. These SNPs may be of great potentials for
future studies of their biological functions. The predic-
tive values of haplotypes, defined by combinations of the
M haplogroup status with non-diagnostic but frequent
SNPs, for the risks of HBV-HCC and alcohol-HCC are
very provocative. The current study provides the evi-
dence that these frequent SNPs nested within selected
haplogroup may become useful predictors for cancer
risk.
Mutations in the D-Loop region are also frequent in
HBV-HCC and the frequency of 21/49 (42.9%, Table 5) is
comparable to a report (39.3 % )f r o ma n o t h e rC h i n e s e
population [25]. The alcohol-HCC group appears to have
a similarly high mutation frequency (4/11, 36.4%). The
309C/ins or 309C/del is still the most common type of
mutation, as seen by others in many types of tumors
[20,27]. Seventeen of the 60 HCC patients harbored
somatic deletions/insertions at this mononucleotide
repeat. The 309 repeat is part of the CSBII, which contri-
butes to the formation of a persistent RNA-DNA hybrid
to initiate the mtDNA replication [20,29,30], Some severe
alteration in this repeat could lead to functional impair-
ment of mitochondria and promote a growth advantage
for tumor cell. Base changes persistent from adjacent
noncancerous to cancerous areas in 4 of 21 HBV-HCC
and 1 of 4 alcohol-HCC patients with mutations suggest
that sequence alteration may occur early and may play a
role in tumorigenesis. Mutation in adjacent non-tumor
tissue with normal morpholog y ,a l s oo b s e r v e db yo t h e r s
[17,19], does not appear to be an incidental finding.
Although the mechanism of mutation is still unclear,
free radicals generated in mitochondria could be responsi-
ble at least partly for these mutations. The D-loop region
of mtDNA is important for regulation of mitochondrial
genome replication and expression. Mutation in this
region may affect mtDNA replication and may alter
Table 4 Comparison of SNP frequencies with different 489 status among subject groups
SNPs Control (n = 38) HBV-HCC (n = 49) Alcohol-HCC (n = 11) P value
d
489T/152T 19 (50.0)
c 13 (26.5) 3 (27.3) >0.9999
P value 0.0243 0.3028
489C/152T 11 (28.9) 18 (36.7) 8 (72.7) 0.0437
P value 0.4447 0.0139
489C/249A 13 (34.2) 19 (38.8) 8 (72.7) 0.0513
P value 0.6614 0.0372
489C/309C 6 (15.8) 12 (24.5) 6 (54.5) 0.0706
P value 0.3204 0.0158
489T/523A 19 (50.0) 11 (22.4) 3 (27.3) 0.7075
P value 0.0073 0.3028
489C/523Del 2 (5.3) 6 (12.2) 6 (54.5) 0.0051
P value 0.4571 0.0007
489T/525C 18 (47.4) 10 (20.4) 3 (27.3) 0.6899
P value 0.0076 0.3106
489C/525Del 3 (7.9) 6 (12.2) 6 (54.5) 0.0051
P value 0.7256 0.0020
aHCC vs. control (Number/patient: unpaired T test; SNP-defined haplotypes: Fisher’s Exact test, otherwise chi-square analysis to obtain values in italic).
bMean ± standard deviation.
cNumber in parenthesis: percentage.
dHBV-HCC vs. Alcohol-HCC.
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early stage of hepatocarcinogenesis. Our data demon-
strated that the utility of SNPs and mutations in mito-
chondria D-Loop region to predict HCC risk and to
differentiate HCCs with distinct etiology. The utility of
mtDNA SNPs for prediction of HCC risks from different
environmental exposures is a promising area for future
cancer prevention. Our results links genetic variation of
exonuclear genome with cancer risk, subsequent research
for SNP in D-loop is more difficult to perform than SNP
in individual genes which can be compared by expres-
sional levels, protein property and interacted genes. Future
experiments with a large sample size are needed to explore
the usage of those minor alleles and to validate the predic-
tive values of SNPs identified in this pilot study.
Additional material
Additional file 1: Table S1: Statitical significance of the pairwise
linkage disequilibrium analysis among SNP in mitochondrial D-loop.
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